Omae Mariko, Inaba Muneo, Sakaguchi Yutaku, Tsuda Masanobu, Miyake Takashi, Fukui Jyunichi, Iwai Hiroshi, Yamashita Toshio, Ikehara Susumu
First Department of Pathology, Kansai Medical University, Osaka, Japan.
Stem Cells Dev. 2008 Apr;17(2):291-302. doi: 10.1089/scd.2007.0075.
The long-term maintenance of hematopoietic stem cells (HSCs) is assessed by serial bone marrow transplantation (BMT), in which HSCs are injected intravenously. Recently, we have found that intra-bone marrow (IBM)-BMT can efficiently reconstitute the hematopoietic system with cells of donor origin, in contrast to conventional intravenous (i.v.) BMT. In the present study, we have compared the long-term maintenance of HSCs using multiple rounds of serial i.v.-BMT and IBM-BMT. The frequencies of donor-derived progenitor cells (Lin(-)/c-kit(+) cells) and more primitive progenitors (Lin(-)/c-kit(+)/CD34(+)/Sca-1(+) cells) were higher in the tertiary recipients by serial IBM-BMT than in those that had received bone marrow cells by serial i.v.-BMT. Furthermore, neither donor-derived progenitor cells nor mature hematolymphoid cells were detected in approximately 25% of the tertiary recipients after serial i.v.-BMT, indicating that progenitor cells can be efficiently maintained by IBM-BMT but not by i.v.-BMT. Finally, we confirmed that the recipients treated with the primary IBM-BMT (without carrying out serial BMT) showed a significantly higher survival rate than those treated with i.v.-BMT. These findings clearly show that IBM-BMT efficiently promotes the longterm maintenance of donor-derived hematopoiesis.
通过连续骨髓移植(BMT)评估造血干细胞(HSC)的长期维持情况,其中造血干细胞通过静脉注射。最近,我们发现与传统静脉内(i.v.)BMT相比,骨髓内(IBM)-BMT能够有效地用供体来源的细胞重建造血系统。在本研究中,我们比较了使用多轮连续静脉内BMT和IBM-BMT时造血干细胞的长期维持情况。连续IBM-BMT的三级受体中供体来源的祖细胞(Lin(-)/c-kit(+)细胞)和更原始的祖细胞(Lin(-)/c-kit(+)/CD34(+)/Sca-1(+)细胞)的频率高于通过连续静脉内BMT接受骨髓细胞的受体。此外,在连续静脉内BMT后的三级受体中,约25%未检测到供体来源的祖细胞或成熟的血液淋巴细胞,这表明祖细胞可以通过IBM-BMT有效维持,但不能通过静脉内BMT维持。最后,我们证实接受初次IBM-BMT(未进行连续BMT)治疗的受体的存活率明显高于接受静脉内BMT治疗的受体。这些发现清楚地表明,IBM-BMT有效地促进了供体来源造血的长期维持。